BioCentury | Jul 19, 2019
Product Development

Why GammaDelta would do its Takeda build-to-buy all over again

...a series of CAR γδ T cells in preclinical development with partners bluebird bio Inc., Scotia...
...Cancer Center, New York, N.Y. Nipro Corp. (Tokyo:8086), Osaka, Japan Noile-Immune Biotech Inc., Tokyo, Japan Scotia...
BioCentury | Mar 19, 2019
Regulation

Talk less, do more: Germline gene editing needs real plans, not just moratoria

...Cambridge, Mass. China Ministry of Science and Technology (MOST), Beijing, China Dalhousie University, Halifax, Nova Scotia...
BioCentury | May 11, 2018
Company News

TC BioPharm, Scotia Biologics in immuno-oncology deal

...TC BioPharm Ltd. (Edinburgh, U.K.) and Scotia Biologics (Aberdeen, U.K.) partnered to co-develop CAR T cell...
...They will also explore the use of CD4 to target lymphoblastic leukemia and HIV infection. Scotia...
...Dec. 8, 2017) . Scotia Biologics, Aberdeen, U.K. TC BioPharm Ltd., Edinburg, U.K. Business: Cancer Sandi Wong Scotia...
BioCentury | May 8, 2018
Company News

TC Biopharm, Scotia Biologics in immuno-oncology deal

...TC BioPharm Ltd. (Edinburgh, U.K.) and Scotia Biologics (Aberdeen, U.K.) partnered to co-develop CAR T cell...
...They will also explore the use of CD4 to target lymphoblastic leukemia and HIV infection. Scotia...
BioCentury | Mar 30, 2018
Finance

Bug money

...and their ability to penetrate biofilms. Companies and Institutions Mentioned Appili Therapeutics Inc., Halifax, Nova Scotia...
BioCentury | Feb 9, 2018
Clinical News

Immunovaccine reports Phase Ib data of DPX-Survivac plus epacadostat for ovarian cancer

...Phase Ib trial (see BioCentury, Aug. 3, 2015 ). Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF), Halifax, Nova Scotia...
BioCentury | Jun 2, 2017
Clinical News

Immunovaccine begins Phase Ib/II of HPV-related cancer vaccine DPX-E7

...Human papillomavirus -16; HpV16gp2) formulated with DepoVax platform technology. Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF), Halifax, Nova Scotia...
BioCentury | Jun 1, 2017
Financial News

Immunovaccine raises C$10M in bought deal

...Wealth Partners, National Bank Financial and Mackie Research Capital. Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF), Halifax, Nova Scotia Alex...
BioCentury | Apr 14, 2017
Clinical News

DPX-RSV: Additional Ph I data

...from the trial (see BioCentury, July 25, 2016 ). Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF), Halifax, Nova Scotia...
BioCentury | Feb 9, 2017
Company News

Immunovaccine, Merck deal

...survivin (BIRC5)-based peptide antigens formulated using DepoVax adjuvanting platform. Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF), Halifax, Nova Scotia...
Items per page:
1 - 10 of 313
BioCentury | Jul 19, 2019
Product Development

Why GammaDelta would do its Takeda build-to-buy all over again

...a series of CAR γδ T cells in preclinical development with partners bluebird bio Inc., Scotia...
...Cancer Center, New York, N.Y. Nipro Corp. (Tokyo:8086), Osaka, Japan Noile-Immune Biotech Inc., Tokyo, Japan Scotia...
BioCentury | Mar 19, 2019
Regulation

Talk less, do more: Germline gene editing needs real plans, not just moratoria

...Cambridge, Mass. China Ministry of Science and Technology (MOST), Beijing, China Dalhousie University, Halifax, Nova Scotia...
BioCentury | May 11, 2018
Company News

TC BioPharm, Scotia Biologics in immuno-oncology deal

...TC BioPharm Ltd. (Edinburgh, U.K.) and Scotia Biologics (Aberdeen, U.K.) partnered to co-develop CAR T cell...
...They will also explore the use of CD4 to target lymphoblastic leukemia and HIV infection. Scotia...
...Dec. 8, 2017) . Scotia Biologics, Aberdeen, U.K. TC BioPharm Ltd., Edinburg, U.K. Business: Cancer Sandi Wong Scotia...
BioCentury | May 8, 2018
Company News

TC Biopharm, Scotia Biologics in immuno-oncology deal

...TC BioPharm Ltd. (Edinburgh, U.K.) and Scotia Biologics (Aberdeen, U.K.) partnered to co-develop CAR T cell...
...They will also explore the use of CD4 to target lymphoblastic leukemia and HIV infection. Scotia...
BioCentury | Mar 30, 2018
Finance

Bug money

...and their ability to penetrate biofilms. Companies and Institutions Mentioned Appili Therapeutics Inc., Halifax, Nova Scotia...
BioCentury | Feb 9, 2018
Clinical News

Immunovaccine reports Phase Ib data of DPX-Survivac plus epacadostat for ovarian cancer

...Phase Ib trial (see BioCentury, Aug. 3, 2015 ). Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF), Halifax, Nova Scotia...
BioCentury | Jun 2, 2017
Clinical News

Immunovaccine begins Phase Ib/II of HPV-related cancer vaccine DPX-E7

...Human papillomavirus -16; HpV16gp2) formulated with DepoVax platform technology. Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF), Halifax, Nova Scotia...
BioCentury | Jun 1, 2017
Financial News

Immunovaccine raises C$10M in bought deal

...Wealth Partners, National Bank Financial and Mackie Research Capital. Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF), Halifax, Nova Scotia Alex...
BioCentury | Apr 14, 2017
Clinical News

DPX-RSV: Additional Ph I data

...from the trial (see BioCentury, July 25, 2016 ). Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF), Halifax, Nova Scotia...
BioCentury | Feb 9, 2017
Company News

Immunovaccine, Merck deal

...survivin (BIRC5)-based peptide antigens formulated using DepoVax adjuvanting platform. Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF), Halifax, Nova Scotia...
Items per page:
1 - 10 of 313